Iron chelators as mitophagy agents: Potential and limitations

Author
Babula, Petr
Přibyl, Tomáš
Zelenka, Jaroslav
Ruml, Tomáš
Publication date
2024Published in
Biomedicine & PharmacotherapyPublisher / Publication place
ElsevierVolume / Issue
179 (October)ISBN / ISSN
ISSN: 0753-3322ISBN / ISSN
eISSN: 1950-6007Funding Information
MSM//SVV260637
MSM//SVV260521
UK//COOP
MSM//LM2023053
TA0//TN02000109
MZ0//NU22-08-00160
MZ0//NU21-08-00407
MSM//LX22NPO5104
MSM//LX22NPO5107
MSM//LX22NPO5102
MV0//VB02000056
Metadata
Show full item recordCollections
This publication has a published version with DOI 10.1016/j.biopha.2024.117407
Abstract
Mitochondrial autophagy (mitophagy) is very important process for the maintenance of cellular homeostasis, functionality and survival. Its dysregulation is associated with high risk and progression numerous serious diseases (e.g., oncological, neurodegenerative and cardiovascular ones). Therefore, targeting mitophagy mechanisms is very hot topic in the biological and medicinal research. The interrelationships between the regulation of mitophagy and iron homeostasis are now becoming apparent. In short, mitochondria are central point for the regulation of iron homeostasis, but change in intracellular cheatable iron level can induce/repress mitophagy. In this review, relationships between iron homeostasis and mitophagy are thoroughly discussed and described. Also, therapeutic applicability of mitophagy chelators in the context of individual diseases is comprehensively and critically evaluated.
Keywords
Mitophagy, Iron heomeostais, Iron chelators, Cancer, Neurodegenerative diseases, Cardiovascular diseases,
Permanent link
https://hdl.handle.net/20.500.14178/2690License
Full text of this result is licensed under: Creative Commons Uveďte původ 4.0 International
